Category: carcinoid and neuroendocrine tumor treatments

Carcinoid Cancer Foundation’s May 2011 Symposium Now Online

June 23, 2011

The Carcinoid Cancer Foundation is pleased to share with you videos from its carcinoid/NET symposium, “Neuroendocrine Tumor Management:  The Era of Personalized Medicine,” held on May 1, 2011 at Mt. Sinai Medical Center in New York City.

Following …

READ MORE
siemens biograph mmr system1

Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community

June 12, 2011

The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100  abstracts on carcinoid

READ MORE
pfizer logo1

Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients

May 20, 2011

The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread  (metastasized) to …

READ MORE
Pfizer logo

Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients

May 20, 2011

The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread  (metastasized) to …

READ MORE
novartis oncology logo1

Carcinoid Cancer Foundation Thanks Symposium Sponsors

April 21, 2011

There’s still time to register for the Carcinoid Cancer Foundation’s 14th annual  symposium for patients, family, friends, and healthcare professionals, which will be held on Sunday, May 1st at Mount Sinai Medical Center in New York City.  The Foundation…

READ MORE
Multidisciplinary Team at Bad Berka

1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)

April 5, 2011

Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …

READ MORE
glucomedix1

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

March 23, 2011

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim

READ MORE
dsc2397 copyw outshadowsharp1

Carcinoid Cancer Foundation Symposium Features Leading NET Cancer Specialists & a Patient Panel

March 5, 2011

What are the most state-of-the-art treatments for carcinoid and NET cancer patients today?  Join us on May 1st when the Carcinoid Cancer Foundation presents its 14th Annual Symposium, “Neuroendocrine Tumor Management: The Era of Personalized

READ MORE
simron singh md1

Carcinoid Cancer Foundation Thanks Steve Jobs for Bringing about Greater Awareness of Neuroendocrine Cancers

January 28, 2011

Since the announcement was made earlier this month that Apple’s CEO Steve Jobs would be taking a medical leave of absence there has been significant media coverage about pancreatic neuroendocrine tumors, NET cancer, and carcinoid.  Although…

READ MORE

Fortune Reports That Steve Jobs Sought Neuroendocrine Cancer Treatment in Switzerland

January 18, 2011

Fortune reported today, January 18, 2011, that Apple’s CEO Steve Jobs went to Basel, Switzerland in 2009 seeking treatment for neuroendocrine cancer. Read the story HERE.…

READ MORE